Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Medtronic
Moodys
McKinsey
Express Scripts

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

VIVLODEX Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Vivlodex, and what generic alternatives are available?

Vivlodex is a drug marketed by Zyla and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in seventeen countries.

The generic ingredient in VIVLODEX is meloxicam. There are twenty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vivlodex

A generic version of VIVLODEX was approved as meloxicam by CIPLA on July 19th, 2006.

  Try it Free

Paragraph IV (Patent) Challenges for VIVLODEX
Tradename Dosage Ingredient NDA Submissiondate
VIVLODEX CAPSULE;ORAL meloxicam 207233 2017-01-09

US Patents and Regulatory Information for VIVLODEX

VIVLODEX is protected by four US patents.

Patents protecting VIVLODEX

Formulation of meloxicam
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Formulation of meloxicam
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Formulation of meloxicam
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM

Formulation of meloxicam
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-001 Oct 22, 2015 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-002 Oct 22, 2015 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-001 Oct 22, 2015 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-002 Oct 22, 2015 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-001 Oct 22, 2015 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.